We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+1.13%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$10.4B
AUM Growth
-$279M
(-2.6%)
Cap. Flow
-$218M
Cap. Flow
% of AUM
-2.1%
Top 10 Holdings %
Top 10 Hldgs %
17.29%
Holding
1,364
New
413
Increased
268
Reduced
302
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$105M |
| 2 |
EMC
EMC CORPORATION
EMC
|
+$103M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$97.6M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$77.4M |
| 5 |
Humana
HUM
|
+$71.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$125M |
| 2 |
Perrigo
PRGO
|
+$103M |
| 3 |
AGN
Allergan plc
AGN
|
+$99.6M |
| 4 |
Pfizer
PFE
|
+$90M |
| 5 |
Viatris
VTRS
|
+$88.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.63% |
| 2 | Healthcare | 15.57% |
| 3 | Communication Services | 13.26% |
| 4 | Technology | 11.56% |
| 5 | Financials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
TJX Companies
TJX
$170B
| $5.47M | 0.05% |
139,718
+128,154
| +1,108% | +$4.65M |
|
327
Robert Half
RHI
$3.61B
| $5.46M | 0.05% |
117,300
-314,114
| -73% | -$13.2M |
|
328
Intuitive Surgical
ISRG
$121B
| $5.38M | 0.05% |
80,496
-2,286
| -3% | -$142K |
|
329
Principal Financial Group
PFG
$23.6B
| $5.36M | 0.05% |
+135,795
| New | +$5.22M |
|
330
Darling Ingredients
DAR
$9.93B
| $5.35M | 0.05% |
406,324
+25,570
| +7% | +$258K |
|
|
BEAV
331
DELISTED
B/E Aerospace Inc
BEAV
| $5.28M | 0.05% |
114,482
-997,303
| -90% | -$42.7M |
|
332
Marathon Petroleum
MPC
$90.3B
| $5.25M | 0.05% |
141,265
-192,835
| -58% | -$7.33M |
|
|
SCU
333
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $5.25M | 0.05% |
120,567
+39,409
| +49% | +$1.86M |
|
|
DNR
334
DELISTED
Denbury Resources, Inc.
DNR
| $5.19M | 0.05% |
2,336,257
-247,075
| -10% | -$411K |
|
335
Scholastic
SCHL
$796M
| $5.13M | 0.05% |
+137,240
| New | +$4.89M |
|
336
Maximus
MMS
$3.14B
| $5.08M | 0.05% |
96,504
+70,713
| +274% | +$3.61M |
|
337
MetLife
MET
$61B
| $5.05M | 0.05% |
+128,981
| New | +$4.82M |
|
|
SHPG
338
DELISTED
Shire pic
SHPG
| $5.04M | 0.05% |
29,339
-8,859
| -23% | -$1.48M |
|
339
Corning
GLW
$126B
| $5.04M | 0.05% |
241,127
+163,065
| +209% | +$3.02M |
|
|
CPN
340
DELISTED
Calpine Corporation
CPN
| $5.03M | 0.05% |
331,523
-531,169
| -62% | -$7.45M |
|
|
MDVN
341
DELISTED
MEDIVATION, INC.
MDVN
| $5.01M | 0.05% |
108,894
+1,776
| +2% | +$64.4K |
|
|
EAGLU
342
DELISTED
Double Eagle Acquisition Corp.
EAGLU
| $5M | 0.05% |
500,000
| – | – |
|
|
PACEU
343
DELISTED
Pace Holdings Corp.
PACEU
| $5M | 0.05% |
500,000
| – | – |
|
|
GRSHU
344
DELISTED
Gores Holdings, Inc.
GRSHU
| $4.99M | 0.05% |
500,000
| – | – |
|
345
Churchill Downs
CHDN
$6.03B
| $4.94M | 0.05% |
200,406
+55,344
| +38% | +$1.26M |
|
|
AMED
346
DELISTED
Amedisys
AMED
| $4.9M | 0.05% |
+101,284
| New | +$3.91M |
|
347
Cable One
CABO
$213M
| $4.89M | 0.05% |
11,192
+4,880
| +77% | +$2.08M |
|
348
Monster Beverage
MNST
$91.4B
| $4.89M | 0.05% |
+219,912
| New | +$4.9M |
|
349
SM Energy
SM
$7.96B
| $4.87M | 0.05% |
259,696
+230,450
| +788% | +$3.18M |
|
350
Prothena Corp
PRTA
$458M
| $4.85M | 0.05% |
+117,937
| New | +$4.62M |
|
Similar funds
Marshall Wace's Q1 2016 Portfolio in Review
As of Q1 2016, Marshall Wace held 1,364 positions worth $10.4B, down 2.6% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Marshall Wace's Q1 2016 filing shows 413 new, 268 increased, 302 reduced and 358 closed positions. Its largest new stake was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M. The largest sale was Bristol-Myers Squibb, an estimated $125M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 12% a quarter earlier, followed by Healthcare and Communication Services.
- Marshall Wace's largest Q1 2016 buy was iShares MSCI Emerging Markets ETF: 3,149,620 shares worth $108M.
- Marshall Wace added most to Adobe in Q1 2016, an estimated $105M increase.
- Marshall Wace's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $125M.
- Marshall Wace fully exited Perrigo in Q1 2016, selling an estimated $103M.
- Marshall Wace's ten largest holdings make up 17% of its $10.4B portfolio in Q1 2016.
- Marshall Wace opened 413 new positions and closed 358 in Q1 2016.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $10.4B.
Based on Marshall Wace's 13F filing for Q1 2016, filed 13 May 2016.